At the AGM held earlier today the CEO, Jeremy Haigh, made a brief statement: 'As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT® strengthens. Trading is broadly in line with expectations despite a characteristically slower first quarter, and the services business continues to demonstrate significant growth. While the Company remains cash constrained, we have had discussions with a number of our larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business.'

All resolutions at the AGM were duly passed.

View PDF Version

« Back To News

Attachments

  • Original document
  • Permalink

Disclaimer

Proteome Sciences plc published this content on 30 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 May 2018 13:57:04 UTC